LAVA Therapeutics N.V. (LVTX)

NASDAQ: LVTX · IEX Real-Time Price · USD
3.78
+0.09 (2.44%)
At close: Feb 3, 2023, 4:00 PM
3.63
-0.15 (-3.97%)
After-hours: Feb 3, 2023, 7:30 PM EST
2.44%
Market Cap 99.37M
Revenue (ttm) 18.89M
Net Income (ttm) -31.06M
Shares Out 26.29M
EPS (ttm) -1.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 12,510
Open 3.83
Previous Close 3.69
Day's Range 3.62 - 3.83
52-Week Range 2.28 - 7.38
Beta n/a
Analysts Buy
Price Target 16.96 (+348.68%)
Earnings Date Mar 23, 2023

About LVTX

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 25, 2021
Employees 55
Stock Exchange NASDAQ
Ticker Symbol LVTX
Full Company Profile

Financial Performance

In 2021, LVTX's revenue was 5.00 million, an increase of 42.86% compared to the previous year's 3.50 million. Losses were -45.35 million, 192.4% more than in 2020.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for LVTX stock is "Buy." The 12-month stock price forecast is $16.96, which is an increase of 348.68% from the latest price.

Price Target
$16.96
(348.68% upside)
Analyst Consensus: Buy
Stock Forecasts

News

LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium

UTRECHT, The Netherlands and PHILADELPHIA, Jan. 23, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platfo...

1 week ago - GlobeNewsWire

LAVA Therapeutics Announces Appointment of New Directors to the Board

Peter A. Kiener, DPhil and Mary E. Wadlinger to Join LAVA Board Peter A. Kiener, DPhil and Mary E. Wadlinger to Join LAVA Board

1 month ago - GlobeNewsWire

LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

UTRECHT, The Netherlands and PHILADELPHIA, Jan. 03, 2023 (GLOBE NEWSWIRE) --  LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gamm...

1 month ago - GlobeNewsWire

LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

Poster presentation to include initial data from subcutaneous administration and updates on intravenous dosing-cohorts Poster presentation to include initial data from subcutaneous administration and ...

2 months ago - GlobeNewsWire

Can LAVA Therapeutics N.V. (LVTX) Climb 198% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for LAVA Therapeutics N.V. (LVTX) points to a 197.6% upside in the stock.

2 months ago - Zacks Investment Research

LAVA Therapeutics N.V. (LVTX) Q3 Earnings Surpass Estimates

LAVA Therapeutics N.V. (LVTX) delivered earnings and revenue surprises of 157.14% and 38.96%, respectively, for the quarter ended September 2022.

2 months ago - Zacks Investment Research

LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results

UTRECHT, The Netherlands and PHILADELPHIA, Nov. 16, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gam...

2 months ago - GlobeNewsWire

Will LAVA Therapeutics N.V. (LVTX) Report Negative Q3 Earnings?

LAVA Therapeutics N.V. (LVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

2 months ago - Zacks Investment Research

LAVA Therapeutics to Present at the Jefferies London Healthcare Conference

UTRECHT, The Netherlands and PHILADELPHIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gamma...

3 months ago - GlobeNewsWire

LAVA Therapeutics to Present Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

UTRECHT, The Netherlands and PHILADELPHIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V.  ( Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Ga...

3 months ago - GlobeNewsWire

LAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial Officer

UTRECHT, The Netherlands and PHILADELPHIA, Nov. 01, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gamma...

3 months ago - GlobeNewsWire

LAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1/2a Clinical Trial of LAVA-051 at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

UTRECHT, The Netherlands and PHILADELPHIA, Oct. 07, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gam...

4 months ago - GlobeNewsWire

What Is Going on With Lava Therapeutics (LVTX) Stock Today?

Source: Shutterstock.com Lava Therapeutics (NASDAQ: LVTX) stock is rocketing higher on Monday as investors react to news of an exclusive global license agreement with Seagen(NASDAQ: SGEN). This agre...

4 months ago - InvestorPlace

Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors

BOTHELL, Wash. & UTRECHT, Netherlands & PHILADELPHIA--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and LAVA Therapeutics N.V. (Na...

Other symbols: SGEN
4 months ago - Business Wire

LAVA Therapeutics N.V. (LVTX) Upgraded to Buy: Here's What You Should Know

LAVA Therapeutics N.V. (LVTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

5 months ago - Zacks Investment Research

LAVA Therapeutics N.V. (LVTX) Reports Q2 Loss, Lags Revenue Estimates

LAVA Therapeutics N.V. (LVTX) delivered earnings and revenue surprises of 49.18% and 53.20%, respectively, for the quarter ended June 2022.

5 months ago - Zacks Investment Research

LAVA Therapeutics Provides Business Update and Reports Second Quarter Financial Results

UTRECHT, The Netherlands and PHILADELPHIA, Sept. 13, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Ga...

5 months ago - GlobeNewsWire

LAVA Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

UTRECHT, The Netherlands and PHILADELPHIA, Sept. 07, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gamm...

5 months ago - GlobeNewsWire

LAVA Therapeutics N.V. (LVTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

LAVA Therapeutics N.V. (LVTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

6 months ago - Zacks Investment Research

LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Program, LAVA-051, in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients

Clinical update call featuring LAVA-051 investigator Dr. Arnon Kater and Company management summarized initial Phase 1/2a clinical trial data presented at 2022 ASCO and EHA meetings Clinical update ca...

8 months ago - GlobeNewsWire

LAVA Therapeutics Announces Two Appointments to its Board of Directors

James Noble and Jay Backstrom, M.D, M.P.H, bring vast global leadership experiences at public biopharmaceutical companies James Noble and Jay Backstrom, M.D, M.P.H, bring vast global leadership experi...

8 months ago - GlobeNewsWire

LAVA Therapeutics to Participate at the Jefferies Healthcare Conference

UTRECHT, The Netherlands and PHILADELPHIA, June 02, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gamma...

8 months ago - GlobeNewsWire

LAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

LAVA Therapeutics to host clinical results conference call and webcast on June 16 at 8:00 a.m. EDT/2:00 p.m. CEST LAVA Therapeutics to host clinical results conference call and webcast on June 16 at 8...

8 months ago - GlobeNewsWire

LAVA Therapeutics Announces Annual Meeting of Shareholders

UTRECHT, The Netherlands and PHILADELPHIA, May 31, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX) (LAVA), a clinical stage immuno-oncology company focused on developing its proprietary...

8 months ago - GlobeNewsWire

LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results

UTRECHT, The Netherlands and PHILADELPHIA, May 17, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gamm...

9 months ago - GlobeNewsWire